LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update OVATION 2 Translational Data Presented at ESMO On June 18, 2025, Imunon, Inc. (NASDAQ:IMNN) announced the presentation of translational data ...

LAWRENCEVILLE, N.J. - IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company with a market capitalization of $24.07 million, presented new translational data from its Phase 2 OVATION 2 ...

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

IMUNON has initiated the pivotal Phase 3 OVATION 3 Study of IMNN-001, with the first two trial sites launched in May 2025. The company reports that IMNN-001 continues to show a favorable safety ...

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 Provided by GlobeNewswire Jun 18, 2025, 5:05:00 AM ...

In May 2025, IMUNON announced positive six-month data from the Phase 1 trial demonstrating better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 ...

Imunon, Inc. (NASDAQ:IMNN), a pharmaceutical preparations company currently trading at $1.32 with a market capitalization of $29.2 million, has regained compliance with Nasdaq’s minimum bid ...

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized ...

IMUNON, Inc. has completed a private placement raising approximately $3.25 million through the sale of 7,222,223 shares of its common stock and accompanying short-term warrants to purchase an ...